Skip to content
Review Open access

Natural compounds targeting glial activation in Alzheimer’s disease: a review of curcumin, resveratrol, and luteolin

Sep 2026 · Exploration of Neuroprotective Therapy · Vol 6 · 0 citations · 91 references

TL;DR

Preclinical evidence suggests that these natural substances show potential as therapeutic candidates for Alzheimer’s disease, although further clinical studies are still needed to confirm their efficacy and safety.

Abstract

Alzheimer’s disease, a neurodegenerative disease, is caused by the accumulation of amyloid-β (Aβ) protein and hyperphosphorylation of Tau protein in the brain, resulting in decreased cognitive function and memory. Neuroinflammation, which is the body’s defense mechanism in the brain, is one of the factors that can worsen the condition of Alzheimer’s patients. The activity of glial cells, such as microglia and astrocytes, causes the release of proinflammatory cytokines that can damage the neurons. However, currently available therapies can only address the symptoms of Alzheimer’s disease. Therefore, alternative strategies are needed that can be used to overcome Alzheimer’s disease, such as the use of natural compounds that have therapeutic potential. The purpose of this article is to discuss the potential of natural substances, such as curcumin, resveratrol, and luteolin, in modulating neuroinflammation. Curcumin, a compound contained in rhizome plants, has been shown to inhibit neuroinflammation by inhibiting the activation of innate immune signalling pathways and suppressing microglia activity. Resveratrol, a polyphenol in plants, has been reported to reduce neuroinflammation by modulating the Sirtuin 1 signalling pathway and polarizing microglia. Luteolin, a plant secondary metabolite belonging to the flavonoid group, is reported to be effective in reducing the production of reactive astrocytes and inhibits the p38 MAPK pathway to reduce neuroinflammation. Overall, preclinical evidence suggests that these natural substances show potential as therapeutic candidates for Alzheimer’s disease, although further clinical studies are still needed to confirm their efficacy and safety.

Read PDF

Similar papers

Open access Oct 2026

"Pharmacological Modulation of Neuroinflammation in Alzheimer's Disease: Current Advances, Emerging Therapeutic Targets, and Future Perspectives"

The gradual degeneration of brain cells, known as synapses and neurones, is the main cause of memory loss and cognitive dysfunction in Alzheimer's disease (AD), a neurodegenerative disorder. Chronic neuroinflammation is an important factor in the development and advancement of the illness, with characteristic pathologi...

Vaishnavi Vijay, Patil, Vaishnavi Mahesh Patil et al. · 0 citations
Review Open access Sep 2026

The Role of Curcumin in Neurogenesis and Neuroprotection in Alzheimer’s disease: From Molecular Mechanisms to Clinical Evidence

This review discusses multi-target neuroprotective mechanisms of curcumin, critically reviews the preclinical success and human clinical trial outcomes, and highlights advanced nano formulations (solid lipid nanoparticles, colloidal sub-micron dispersions, polymeric nanoparticles, multi-walled carbon nanotubes and exos...

V. S, Sarupruthiya M, Jeevitha D et al. · 0 citations
Review Open access Sep 2026

Potential uses of Ginkgo biloba in the treatment of Alzheimer's disease

The general features of dementia and Alzheimer's disease are outlined, current treatment approaches are summarized, and the potential role of Ginkgo biloba is evaluated, with particular emphasis on standardized leaf extracts such as EGb 761 and GBE50, as well as Ginkgo-derived preparations such as Ginexin-F, based on t...

Yaren Oktay, Şuranur Ayvaz, C. Inan et al. · 0 citations
Review Open access Sep 2026

Medicinal Plants and Bioactive Phytochemicals Targeting Neuroinflammation: Molecular Mechanisms, Preclinical Evidence and Translational Challenges

An in-depth review of medicinal plants with anti-neuroinflammatory properties, focusing on their bioactive compounds, mode of action, and clinical applications in neurological disorders is given.

Owemidu Idowu Olumorin · 0 citations
Review Open access Sep 2026

Apigenin-Induced Shifts in Microglial and Astrocytic Polarization: A Potential Therapeutic Strategy for Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β accumulation, tau pathology, synaptic failure, neurovascular dysfunction, mitochondrial injury and chronic neuroinflammation. While amyloid and tau remain central pathological features, the inflammatory state of the brain is...

F. Nikbakht, S. Taherkhani, Fatemeh Jamaliaghdam Dozdozan et al. · 0 citations
Review Sep 2026

Immunity and Inflammation in Alzheimer's Disease: A Narrative Review on Mechanisms and Therapeutic Prospects.

This review systematically summarizes the core pathophysiological mechanisms by which inflammatory and immune dysfunctions contribute to AD pathogenesis and explores potential therapeutic interventions targeting these mechanisms, thereby providing theoretical insights for clinical translational research on AD treatment...

Lu-Ping Chi, Feng-Qing Xu, Xiao-Ying Dai et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.